A New Era in Erectile Dysfunction Management: Oxsedo® (Udenafil) in Jordan

Today, we celebrate a new milestone in our commitment to improving patients’ lives by delivering solutions that enhance health, confidence, and quality of life.

We are proud to announce the launch of Oxsedo®️ (Udenafil), the next generation of PDE5 inhibitor therapy developed in partnership with Dong-A Pharmaceutical, South Korea, and proudly introduced by Misk Pharma as the originator of Udenafil.

This milestone was celebrated through a distinguished scientific launch event held in partnership with the Jordanian Association of Urology, bringing together many of Jordan’s leading urologists. Their participation reflects our shared commitment to advancing clinical excellence and improving patient care through evidence-based innovation.

This launch is more than the introduction of a new therapy. It reflects our vision of making innovative, evidence-based healthcare accessible to patients across Jordan, the MENA region, and beyond. We believe that every patient deserves the opportunity to enjoy life’s meaningful moments with confidence, dignity, and better health.

This is not just the beginning of a product, it is the beginning of a shared journey to improve lives, elevate standards of care, and redefine what is possible for patients worldwide.

Innovation inspired by science. Driven by patients.